Gene therapy biotech Homology Medicines increases proposed IPO deal size ahead of pricing
Homology Medicines, a preclinical biotech developing a gene therapy delivery platform for rare diseases, raised the proposed deal size for its upcoming IPO on Tuesday.
The Bedford, MA-based company now plans to raise $135 million by offering 9 million shares at a price range of $14 to $16. The company had previously filed to offer 6.7 million shares at a range of $14 to $16. At the midpoint of the revised range, Homology Medicines will raise 35% more in proceeds than previously anticipated.
Homology Medicines was founded in 2015 And booked n/a in sales for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol FIXX. BofA Merrill Lynch, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. It is expected to price during the week of March 26, 2018.
The article Gene therapy biotech Homology Medicines increases proposed IPO deal size ahead of pricing originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.